Kymera’s partnerships with Sanofi and Gilead drive value
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Stifel Defending Kymera Therapeutics (KYMR): 'We see any weakness from today's news as a buying opportunity'
June 27, 2025 12:19 PM EDTStifel analyst Alex Thompson reiterated a Buy rating and $68.00 price target on Kymera Therapeutics (NASDAQ: KYMR).
The analyst comments "We are reiterating our Buy Rating on KYMR following a slate of updates including the decision by partner Sanofi to discontinue development of... More
